Alternative Therapeutic Approaches in the Treatment of Primary and Secondary Dedifferentiated and Medullary Thyroid Carcinoma

The prognosis of patients with surgically unresectable differentiated thyroid tumors deteriorates significantly if radioiodine therapy is or becomes ineffective, considering the limited role of conventional chemotherapies in these patients. Several alternative approaches have been investigated for t...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2011-03, Vol.41 (2), p.139-148
Main Authors: Biermann, Kim, MD, Biersack, Hans-Jürgen, MD, Sabet, Amir, MD, Janzen, Viktor, MD
Format: Article
Language:English
Subjects:
Carcinoma, Neuroendocrine
Cell Dedifferentiation - drug effects
Complementary Therapies - methods
Humans
Radiology
Thyroid Neoplasms - metabolism
Thyroid Neoplasms - pathology
Thyroid Neoplasms - secondary
Thyroid Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of patients with surgically unresectable differentiated thyroid tumors deteriorates significantly if radioiodine therapy is or becomes ineffective, considering the limited role of conventional chemotherapies in these patients. Several alternative approaches have been investigated for the treatment of patients with advanced thyroid malignancies in recent years. Among targeted therapies, tyrosine kinase inhibitors have resulted in the most encouraging responses and could soon be, along with redifferentiation therapy, the possible palliative strategies. Radiopeptide therapy, especially with beta emitter-labeled DOTANOC, which shows a great affinity to the somatostatin receptors expressed by thyroid tumor cells, might also be an attractive approach considering its comparatively low rate of side effects. However, the indication should be evaluated on individual basis. Medullary thyroid carcinoma shows a worse overall prognosis compared with the other differentiated thyroid tumors especially because of its natural resistance to radioiodine therapy. However, among possible palliative strategies,131 I-meta-iodobenzylguanidine therapy is a noteworthy therapeutic approach in patients experiencing metastasized medullary thyroid carcinoma. In summary, recent developments in the treatment of patients with advanced thyroid malignancies have shown promising results, raising the hope for better outcomes in these patients in future.
ISSN:0001-2998
1558-4623
DOI:10.1053/j.semnuclmed.2010.10.005